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ABSTRACT
Doxorubicin (DOX) is one of the most widely used anticancer agents. DOX is known for inducing cardi-
otoxicity, resulting in the long-term development of heart failure. Intravascular delivery of DOX may
benefit from the carriage by red blood cells (RBCs), as they can limit the systemic toxicity while deliv-
ering the DOX to the tumor. This study proposes a methodology for the synthesis of electrophoretic-
ally DOX-loaded red blood cells (RBC-DOX), as well as the assessment of its antitumorigenic effects in
human colon cancer cells (HT-29), and in colon cancer xenograft models. In addition, healthy mice
without tumors were dosed with RBC-DOX to assess cardiotoxicity via assessment of indexes of cardiac
function after multiple doses of RBC-DOX. The HT-29 IC50 was found to be lower for RBC-DOX com-
pared to free DOX. Tumor volume for the RBC-DOX group was smaller than the free DOX groups in
HT-29 xenografts models. Statistically higher concentrations of DOX were found in the liver, spleen,
and lungs for the RBC-DOX group compared to the free DOX group. However, the heart and the skin
had statistically lower DOX concentrations for the RBC-DOX group compared to the free DOX group,
with no significant differences in tumor biodistribution. All hemodynamic and cardiac function param-
eters were closer to control parameters for the RBC-DOX treated compared to for the free DOX-treated
mice. These results suggest that RBC-DOX can be an alternative to prolong treatments with DOX, with
superior antitumorigenic effects, decreased myelosuppression, and limited cardiac toxicity compared
to equivalent doses of free DOX.
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Introduction
Colorectal cancer is the third most common cause of cancer-
associated deaths (Jemal et al., 2010), with a high percentage
of subjects presenting metastatic disease. Despite surgery
and chemotherapy, subjects with colorectal cancer eventually
succumb to metastatic diseases. The success of radiotherapy
and chemotherapy in colorectal cancer is limited by the
resistant cancer cells and the dose-limiting toxicities (Segal &
Saltz, 2009). Anthracyclines, are considered some of the most
effective anticancer drugs available in the market (Weiss,
1992). Doxorubicin (DOX) is one of the most common
anthracyclines, been proven effective against soft tissue and
bone sarcomas, and breast, ovary, bladder, and thyroid can-
cer. It has also been used for the treatment of small cell lung
cancer, Hodgkin’s lymphoma, and acute myeloblastic and
lymphoblastic leukemia (Johnson-Arbor & Dubey, 2018).
However, anthracyclines have well-known side effects, where
amongst the most common is cardiotoxicity (Chatterjee
et al., 2010; Mitry & Edwards, 2016). Doxorubicin cardiomyop-
athy is frequently fatal once developed, as it often evolves
into a form of congestive heart failure unresponsive to treat-
ment (Bristow et al., 1978; Takemura & Fujiwara, 2007). In a
large-scale retrospective cohort study, older women diag-
nosed with breast cancer were followed for a period of
9 years, and the leading cause of death was cardiovascular
disease, followed by breast cancer itself (Patnaik et al., 2011).
Although the severity of the cardiomyopathy is dose-
dependent (Alexander et al., 1979), so is the drug’s effective-
ness, therefore, methods to decrease the exposure of non-
cancerous tissue to DOX, while still maintaining a sufficient
tumor DOX exposure.
An approach that has been in the spotlight since the early
80 s has been the use of liposomes for anticancer drug deliv-
ery, including the delivery of DOX (Gregoriadis, 1985).
Liposomes are nanoscale-sized spheroids with a lipid-based
membrane, which allow the encapsulation of substances as a
means of drug delivery. By enclosing the delivered sub-
stance, they allow for a longer circulation time, and therefore
an increased opportunity for the drug to arrive to the region
of interest. Early efforts in the use of liposomes for the deliv-
ery of DOX, however, were thwarted by the early recognition
of the liposomes by the reticulo-endothelial system, resulting
in fast degradation and plasma clearance (Juliano & Stamp,
1975; Poste 1982). A great body of research has focused on
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the modification of the surface properties of the liposomes
in order to prolong their circulation time and efficacy. One
line of research has focused in adding bulky synthetic groups
such as polyethylene-glycol (PEG) to the surface of DOX-
loaded liposomes, allowing for decreased opsonization, and
therefore, longer circulation times (Gabizon et al., 2003).
However, recent findings relating to PEG-induced immune
response have led to the search for alternatives (Knop et al.,
2010). Some groups have focused in mimicking surface
markers and structural features present in red blood cells
(RBCs) and adding them to the liposomes or nanoparticles
and have been proven successful (Doshi et al., 2009; Parodi
et al., 2013; Li et al., 2014; Luk & Zhang, 2015; Zhai et al.,
2017). However, these techniques often involve multi-step
procedures, and since there is still a synthetic component,
namely the nanoparticle or the liposome, the immune
response is still likely to eventually occur and there is a
potential for toxic byproducts during degradation. Currently,
DOX is clinically administered as DoxilVR , a pegylated liposo-
mal doxorubicin. This formulation is preferred above free
DOX as it prolongs DOX circulation time and avoids reticulo-
endothelial system activation by the liposomal lipid bilayer
due to the use of PEGylated nano-liposomes. DoxilVR has
shown less cardiac toxicity than free DOX on an equimolar
basis, but in both cases the cardiac risk increases with
increased cumulative dose (O’Brien et al., 2004).
Other approaches to mitigate the toxicity of doxorubicin
have embedded DOX inside human serum albumin (HSA)
aggregates, with or without surface modification to increase
tumor specificity (Bae et al., 2012; Zheng et al., 2015). The
surface modifications of the HSA aggregates include the
amino-terminal fragment of urokinase (ATF), which binds
with a high affinity to urokinase receptor overexpressed in
many types of tumors, or the tumor necrosis factor (TNF)-
related apoptosis-inducing ligand (TRAIL) and transferrin to
increase cytotoxic and apoptotic activities (Bae et al., 2012;
Zheng et al., 2015). Although, these approaches reduce the
cardiotoxicity of DOX and increase antitumor efficacy, HSA
based formulations affect plasma protein concentration,
plasma colloid osmotic pressure, and hematocrit pre- and
post-infusion. In addition, as HSA is produced by fraction-
ation of plasma obtained from donors, the theoretical poten-
tial for the transmission of new and reemerging infectious
agents (hepatitis, human immunodeficiency virus, West Nile
virus, etc) with blood- and plasma-derived products is not
unlikely to be eliminated. On the other hand, the use of
RBCs as a bio-compatible, liposome-like, drug delivery alter-
native has been explored extensively (Muzykantov, 2010; Xu
et al., 2016; Sun et al., 2017). The advantage of using RBCs,
as opposed to traditional coated liposomes or nanoparticles,
lies in their superior biocompatibility and absence of toxic
byproducts during degradation, especially when autologous
blood types are used (Pierige et al., 2008). These advantages
come while still preserving the long circulation times and
sustained release ability present in the other drug delivery
approaches (Sun et al., 2017). Furthermore, removing the
need to coat the nanoparticle or liposome, the synthesis pro-
cess can be simplified, increasing efficiency. Additionally,
their specific use for the delivery of DOX has been success-
fully demonstrated previously by two studies, one in humans
for the treatment of lymphoma (Ataullakhanov et al., 1997;
Skorokhod et al., 2007), and one in dogs for the treatment of
lymphosarcoma (Matherne et al., 1994), proving successful in
both cases. Neither of these studies, however, performed an
in-depth analysis of the cardiotoxicity derived from these
loaded cells. Additionally, they did not show any results per-
taining to the biodistribution, myelosuppression, immune
response, and effective cytotoxicity resulting from the use of
doxorubicin-loaded red blood cells (RBC-DOX), all of which
are necessary for a proper understanding of the potential
benefits, and drawbacks, of using RBC-DOX as a delivery
alternative for DOX. We have recently developed a novel
approach to load drugs into red blood cells to use them as
biological carrier systems (Cabrales et al., 2008; Villela
et al., 2009).
We have also demonstrated that the electrophoretically
modified RBCs do not lose hemoglobin (Hb) through hem-
olysis after infusion and that loading drugs in RBCs does not
affect their deformability significantly (Cabrales et al., 2008;
Villela et al., 2009). In this study, we propose a methodology
for the synthesis of RBC-DOX, as well as the assessment of
its antitumorigenic effects in vitro in human adenocarcinoma
HT-29 cells, and in vivo in HT-29 implanted athymic mice.
Myelosuppression, biodistribution and tumor growth were all
assessed in vivo for the HT-29 implanted mice. Healthy mice
were also treated with equivalent formulations of both free
DOX and RBC-DOX, and their systemic hemodynamics and
cardiac function parameters were assessed in order to deter-
mine cardiac toxicity.
Methods
RBC-DOX preparation
Blood was collected from mice donor (25–30 g) into a vacu-
tainer (EDTA). Red cells (RBCs) were isolated and washed
three times by centrifugation. Electroporation was used to
load doxorubicin (DOX) into RBCs. A high voltage pulse gen-
erator BTX T100 (Biotechnologies and Experimental Research,
San Diego, CA) was used to create micropores to allow slow
diffusion of DOX from medium into the RBCs. BTX T100 was
configured to deliver repeated pulses (3.5 kV/cm followed by
an exponential decay, tau = 6 sec) for 3 mins. The electropor-
ation chamber was a modified sterile cuvette (0.5mL) with
parallel stainless steel electrodes separated 2.2mm gap. RBCs
(at 50% Hct) were suspended in saline solution with DOX at
5mg/mL. RBCs were resealed by incubation at 4 C (5min)
followed by 37 C (1 h). Lastly, RBC-DOX were then washed
twice with PBS with 0.5% HSA.
DOX loading efficiency
Doxorubicin loading amount and efficiency were calculated
indirectly by subtracting the measured amount of drug in
washed solution from the initially added drug amount, and
directly after hemolyzing RBCs in methanol. Doxorubicin in
434 A. LUCAS ET AL.
the collected wash solution was analyzed by high-perform-
ance liquid chromatography (HPLC) (Urva et al., 2009). The
HPLC system used was a Hitachi D-7000 series (Hitachi,
Japan); components consisted of a Masterflex L/S Economy
pump (Barnant Company, USA), Hitachi L-7485 fluorescence
detector with excitation and emission wavelength set at 480
and 560 nm, respectively. A mixture of methanol and 10mM
phosphate buffer (pH = 3.0) was used as the mobile phase.
The flow-rate used in the assay was 0.8mL/min and the col-
umn was maintained at 40 C throughout the chromato-
graphic process. The loading efficiency curve is shown in
Supplemental Figure 1.
Colorectal cytotoxicity of DOX-RBC
Human colorectal adenocarcinoma HT-29 cells (ATCC,
Manassas, VA) were cultured at 37 C in 95%O2, 5% CO2. The
cultures were randomized into two groups, DOX and RBC-
DOX, of n¼ 8 wells each. Each well contained 2 103 cells in
McCoy’s 5 A medium with 10% FBS. In the DOX group, DOX
solution ranging in concentration between 0 and 3 mg/mL
was added to each well 24 h after cell plating. Medium was
replaced every 24 h with DOX-RBC or DOX equivalent con-
centration ranging between 0 and 3mg/mL, as dictated by
the loading efficiency curve. After 48 h of incubation, absorb-
ance was measured, and cytotoxicity was expressed as a per-
centage of control cells, which received no treatment. The
inhibition concentration 50% (IC50), defined as the dose of
agents that inhibited 50% of cell growth, was interpolated
from the growth curves. All experiments were performed in
triplicate and repeated several times.
Pharmacokinetics
Tumorless 6–7weeks old mice (C57BL, 20–25g) were adminis-
tered a single intravenous (IV) dose of DOX (n¼ 3) or RBC-
DOX (n¼ 3) at 5mg DOX/kg. Blood samples were collected
in heparinized tubes from the tail at 2min, 0.5 h, 2 h, 6 h, and
24 h. After collection, blood samples were centrifuged to sep-
arate RBCs and plasma. To determine DOX levels in plasma,
200ml of methanol and 200 ml of phosphate buffer were then
added to 25 mL plasma, vortexed for 1min, and centrifuged
again. The supernatant was mixed with 1mL of perchloric
acid (35%, v/v) and vortexed for 1min, and centrifuged one
more time prior measurement of DOX concentration
using HPLC.
Experimental groups
Groups were labeled based on the treatment given, namely:
DOX, for the animals that received free DOX, and RBC-DOX,
for animals that received DOX-loaded RBCs. Where appropri-
ate, control animals were included and were either left
untreated or received saline vehicle solution.
In vivo experimental model
Xenograft tumors were established in 6weeks old female
athymic nude (nu/nu) mice, obtained from Jackson Labs (Bar
Harbor, ME) and maintained under pathogen limited condi-
tions. All animal experiments were performed in accordance
with the guidelines of Institutional Animal Welfare
Committee. Animals were fed ad libitum with a standard
diet. Tumor cells growing exponentially were harvested by
brief incubation with 0.25% trypsin EDTA solution. The cells
were washed and resuspended at a concentration of 3 107
cells/mL in PBS, which was then inoculated subcutaneously
(s. c.) into the right flank of the mice. Tumor size was
assessed using a digital caliper every other day after implant-
ation and approximate tumor volume (mm3) was calculated
as lengthwidth2/2 (V¼ lw2/2). Treatment started when
tumors were 150mm3. Mice were randomized into three
groups DOX, RBC-DOX, and control untreated (n¼ 6 per
group). The DOX received 5mg/kg IV doses twice a week for
4weeks. The RBC-DOX group received an equivalent 5mg/kg
IV doses twice a week for 4weeks. The control group
received no treatment.
DOX biodistribution
Studies comparing the accumulation of free DOX or RBC-
DOX in tumors and organs (liver, spleen, lungs, kidney, heart,
and skin) were performed in the HT-29 tumor xenograft
model. Tissues and tumor were assessed through HPLC after
tissue homogenization after 4weeks (24 days) of treatment.
Analysis of myelosuppression
To evaluate the general myelosuppressive activity of DOX
and RBC-DOX, whole blood was collected into tubes with
EDTA when the mice for therapeutic experiments were sacri-
ficed. Blood cells counts were analyzed using a Hemavet
950FS Multi-Species Hematology System (Drew Scientific, CT)
programed with mouse settings. Additionally, blood smears
were obtained for each animal to obtain a relative white cell
count. Slides were stained with Giesma. The total number of
white cells per 1000 red cells were counted (n¼ 3 for
each slide).
DOX-induced cardiotoxicity model
BALB/c mice weighing 22–25g (Jackson Laboratories, Bar
Harbor, ME) were separated into DOX, RBC-DOX, and control
groups (n¼ 6 per group). The DOX group received 5mg/kg IV
doses of DOX, the RBC-DOX group received 5mg/kg equiva-
lent of DOX and the control group received a vehicle infusion
of saline. The animals were treated at days 0, 3, 6, and 9.
Hemodynamic measurements of heart rate (HR), mean arterial
pressure (MAP), and systemic vascular resistance (SVR) were
completed 5days after final administration. Animals were anes-
thetized using sodium pentobarbital (40mg/kg IP). Animal
preparation included: (i) left femoral artery catheterization, (ii)
tracheotomy (polyethylene-90 tube), and (iii) left ventricle
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conductance catheter introduction through the right carotid
artery. Animals were placed in the supine position on a heat-
ing pad to maintain core body temperature at 37 C. Animals
were mechanically ventilated (TOPO ventilator, Kent Scientific,
CT) using room air (respiration rate of 90 breaths per minute;
peak inspiratory pressure of 20 cmH2O). After instrumentation,
volatile anesthesia (0.6%/vol Isoflurane, Dr€agerwerk AG L€ubeck)
was administered using a vaporizer connected to the ventila-
tor. Deep of anesthesia was continually verified via toe pinch,
if needed, isoflurane was increased by 0.1%/vol to prevent ani-
mal discomfort.
Cardiac function
The closed chest method was used to study cardiac function.
Briefly, the right common carotid artery was exposed to
insert a 1.4 F pressure-volume conductance catheter (pres-
sure-volume PV catheter; SPR-839, Millar Instruments;
Houston, TX). The PV catheter was advanced passing through
the aortic valve into the left ventricle (LV). The pressure and
volume signals were continuously acquired (MPVS300, Millar
Instruments; Houston, TX and PowerLab 8/30, AD
Instruments; Colorado Springs, CO). Left ventricular volume
was measured continuously in conductance units (RVU; rela-
tive volume unit) and converted to actual blood volume (lL)
at the end of the experiment. Parallel volume was calibrated
at the end of the experiment via IV injection of 10mL hyper-
tonic saline (15%). Cardiac function was analyzed with PVAN
software (Millar Instruments, TX). Cardiac function parameters
were averaged from 10–15 cardiac cycles at each time point.
End-systolic pressure (Pes) was directly measured. Maximum
rate of pressure change (dP/dtmax), minimum rate of pressure
change (dP/dtmin), maximum filling volume rate (dV/dtmax),
ejection fraction (EF), cardiac output (CO), and stroke work
(SW) were calculated. Systemic vascular resistance (SVR) was
calculated as SVR¼MAP/CO.
Statistical analysis
Results are presented as mean± standard deviation. As the
data were collected, interim analysis was implemented, and
following animal care regulation, no more animals were
included as statistical significance was reached. Statistically
significant changes between solutions and time points were
analyzed using two-way analysis of variance (two way
ANOVA), followed by post-hoc analyses using Tukey’s mul-
tiple comparisons test when appropriate. All statistics were
calculated using GraphPad Prism 6 (GraphPad, San Diego,
CA). Results were considered statistically significant if p< .05.
Results
Characterization of RBC-DOX
Loading of DOX into RBC was found proportional to the vol-
ume of RBCs used (2.6mg/mL of blood). Intracellular reten-
tion of DOX during storage was determined by taking
advantage of the natural fluorescent property of DOX.
The RBC cellular uptake and retention of DOX was studied
using fluorescent microscopy. In addition, HT-29 cells uptake
of DOX from DOX-RBC was also confirmed via incubation of
DOX-RBC and HT-29 cells for 24 h. After washing, the RBC
and HT-29 cellular uptake of different RBCs electrophoretic-
ally loaded with DOX were evaluated to determine optimal
loading conditions and DOX concentrations. The HT-29 cells
treated with free DOX showed slightly greater red fluores-
cence than those treated with RBC-DOX after 24 h incuba-
tion. However, the retention of DOX in the RBC-DOX in
extended and gradually decreased over 24 h, ensuring the
small amounts of DOX were slowly released to HT-29 cells
ensuring continuous challenge of cells. The prolonged
release and retention of RBC-DOX in vitro suggest that RBCs
might have superior efficacy and reduced toxicity in vivo.
In vitro experimental model
The cytotoxicity of DOX and RBC-DOX in HT-29 cells is
shown in Supplemental Figure 2. The IC50 was 1.77 mg/mL
for the free DOX group, and 1.45 mg/mL for the RBC-DOX
group, as calculated by linear interpolation between the
points around 50%. At the maximum concentration of 3 mg/
mL the median percent survival was 27.55% for free DOX
and 6.65% for RBC-DOX. These results indicate an increased
tumor cytotoxicity for RBC-DOX as compared to DOX.
Pharmacokinetics
The DOX plasma concentration as a function of time for DOX
and DOX-RBC after a single 5mg/kg IV dose is shown in
Figure 1. Table 1 summarizes the comparisons between the
Table 1. Comparison of pharmacokinetics.
Parameter DOX RBC-DOX
Dox dose (mg/kg) 5 5
AUC0–24 h (mg/Lh) 1289 ± 48 3024 ± 89
CL (L/h/kg) 2.79 ± 0.31 1.49þ 0.09
Pharmacokinetic from i.v. injection at 5mg/kg.
Data, means ± SEM; (n¼ 3).
AUC0–24 h: Area under plasma concentration; CL: Total body clearance.
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Figure 1. Plasma concentration of DOX (blue), and RBC-DOX (red), as a func-
tion of time over a 24 h time period after a 5mg/kg intravenous injection.
Corresponding area under the curves and plasma clearance rate are shown in
Table 1.
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two curves. The area under the concentration curve during
the 24 h was statistically higher for RBC-DOX compared to
DOX. The same improvement was found in the plasma con-
centration-time curve. The total body clearance calculated as
the exponential decay time constant of the concentration
curve was statistically greater and almost double for RBC-
DOX compared to DOX. These results indicated a longer last-
ing presence and enhanced bioavailability of DOX in the
body when loaded into RBCs as compared to free DOX.
In vivo experimental model
Figure 2 summarizes the results of the in vivo experimental
model. The tumor volume over time for the in vivo experi-
mental model for free DOX, RBC-DOX, and control is shown
in Figure 2(A). All groups were no different at the beginning
of treatment. At all timepoints tumors treated with RBC-DOX
have a significantly smaller tumor volume as compared to
the untreated control, and after 12 days of treatment signifi-
cantly smaller tumor volume compared to the free DOX
group. The mean final tumor volumes were significantly
smaller for RBC-DOX compared to DOX and untreated con-
trol. The biodistribution of DOX in the free DOX and RBC-
DOX groups is shown in Figure 2(B,C). The liver, spleen, and
the lungs of the RBC-DOX group all had a significantly higher
concentration of DOX, relative to the free DOX group (Figure
2(B)). On the other hand, the skin and the heart had both
lower concentrations of DOX in the RBC-DOX group as com-
pared to the free DOX group (Figure 2(C)). The tumor and
the kidneys both had slightly larger concentrations of DOX
in the RBC-DOX group compared to the free DOX group. Our
data demonstrate that the accumulation of DOX tissues
more susceptible to DOX toxicity was significantly lower than
that of DOX. Since tissue levels of DOX were reduced by
RBC-DOX delivery, the decreased concentration of DOX at
these sites is likely to result in a reduced risk of the develop-
ment of side effects. The increased accumulation of DOX in
the liver, spleen, and lung with RBC-DOX compared to the
free DOX is the results of RBC loaded cells is expected as
these organs have extended capillary networks and are part
of the organs of the reticuloendothelial system.
The myeloid cell counts used to assess myelosuppression
are shown in Figure 3. All cell counts were statistically differ-
ent between each group except for neutrophils when com-
pared between RBC-DOX and control groups, where no
statistical difference between cell counts was found. The
RBC-DOX group had higher counts for all myeloid cell types
than the DOX, and higher monocyte cell count than both
control and free DOX group.
DOX-induced cardiotoxicity model
The systemic hemodynamic results are shown in Figure 4.
HR, CO, and MAP were statistically higher for the RBC-DOX
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group than for the free DOX group. On the other hand, SVR
was higher for the free DOX group than for the RBC-DOX
group. HR, MAP, CO, and SVR values of the RBC-DOX group
approximated the control group values more closely than
the free DOX group values. A similar trend is observed in the
cardiac function parameters (Figure 5(A)), where all parame-
ters related to the heart’s ability to pump blood, namely SV,
EF, SW and dP/dt, were statistically larger, and closer to the
control group, for the RBC-DOX group than for the free DOX
group. The LVSP was also scientifically higher for the RBC-
DOX compared to the free DOX group. The LVDP was statis-
tically lower, and also closer to the control group, for the
RBC-DOX group relative to the free DOX group. The PV loops
from which the functional parameters were derived are
shown in Figure 5(B). These results suggest increased cardiac
performance for the RBC-DOX group as compared to the
free DOX group in all measured hemodynamic and func-
tional parameters.
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work (SW), (D) contractility (dP/dt), (E) left ventricular systolic pressure (LVSP), and (F) left ventricular diastolic pressure (LVDP). (G) shows the PV-loops from which
the cardiac function parameters were derived.
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Discussion
The principal finding of this study is that RBC-DOX has super-
ior anticancer activities and decreased toxicity compared to
equivalent doses of free DOX in a xenograft mouse model of
human colorectal adenocarcinoma. The increased anticancer
effects of RBC-DOX were demonstrated in the in vitro HT-29
cell culture experiments and the extended pharmacological
effects induced by the encapsulation of DOX in the RBCs.
This study shows several important points: (a) RBC-DOX was
readily taken up by colon cancer cells and displayed pro-
longed intravascular retention; (b) encapsulation of DOX in
RBC resulted in a decreased distribution of the drug to the
principal sites of acute and chronic toxicity of free DOX,
namely the heart and the skin, as well as markedly lowered
cardiotoxicity and myelosuppression; (c) RBC-DOX displayed
an enhanced therapeutic efficacy in a xenograft mouse
model of human colorectal adenocarcinoma.
The lower IC50 and the lower percent survival at the max-
imum concentration of 3mg/mL for the RBC-DOX, as com-
pared to free DOX, are indicative of increased tumor
cytotoxicity and potency for the RBC-DOX. In vivo, the
increased antitumorigenic effect was demonstrated by a sig-
nificantly smaller tumor size for the RBC-DOX treated group,
compared to the free DOX group. This increased antitumor
cytotoxicity can be attributed to the liposomal nature of
RBCs. It has been shown extensively that using spherical lipid
vesicles, namely liposomes, as drug carriers for chemothera-
peutic agents increases the agent’s antitumorigenic effects
(Abraham et al., 2005; Niu et al., 2010; Yingchoncharoen
et al., 2016). This effect has been attributed, both in vitro and
in vivo, to the increased permeability of the enclosed drug to
the cellular lipid bilayer, allowing increased drug uptake by
cancerous cells. This effect, however, often involves a drug
enclosing liposome that is at least an order of magnitude
smaller than the enclosing cell. Therefore, when using RBCs,
more complex cell-cell interactions are likely to be taking
place. Another complementary effect of enclosing DOX in
the RBCs is that the diffusion of the drug is now also limited
by the diffusion of the RBCs. This generates higher effective
concentrations of DOX in the regions surrounding clusters of
RBC-DOX. In vitro this allows the drug to be contained in
concentrated regions, potentially accumulating near the
tumor cells and leading to the observed increased antitumor
activity and cytotoxicity. This effect also proves especially
relevant in vivo, since the complex vasculature of tumors are
ideal environments for these clusters to form as the lipo-
somes extravasate to the peritumor region (Yingchoncharoen
et al., 2016). However, the larger size of RBCs as compared
to traditional liposomes might limit this effect, which might
explain why there was not a statistically higher concentration
of DOX in the tumor of the RBC-DOX group as compared to
the free DOX group (Figure 2(C)). Nevertheless, the size of
the tumor in the RBC-DOX group was significantly smaller
than the size of the tumor in the free DOX group, potentially
due to the extended bioavailability of DOX from the
RBC-DOX.
The liposomal nature of the RBCs also plays a role in
maintaining an increased long term effective concentration
of DOX in the body as demonstrated by the pharmacokinet-
ics (Figure 1). Decreased drug clearance from the body,
which is characteristic of liposomes, is often attributed to
decreased immune and renal filtration of the enclosed drug
(Yingchoncharoen et al., 2016). In RBCs, the inherent biomim-
etic ability of the membrane allows for an even superior
avoidance of undesired immune responses or enzymolysis
(Muzykantov, 2010; Xu et al., 2016; Sun et al., 2017).
Extended bioavailability combined with the clustering effects
mentioned before, increased the probability for the drug to
arrive to the peritumor area (Gabizon et al., 2003; Urva et al.,
2009). Since no significant differences in tumor DOX concen-
tration were found between free DOX and RBC-DOX, it is
likely that RBC-DOX resulted in repeated exposures at
equivalent concentrations of DOX over longer periods of
time due to increased bioavailability. The repeated exposure,
resulting from a recurring flow of RBC-DOX through the
tumor vasculature led to a significant decrease in tumor size
without a significant increase in DOX concentration for the
RBC-DOX group. With RBCs as the carrier, the clearance of
RBC-DOX appears to involve the spleen and the liver. This is
supported by the DOX biodistribution results, where statistic-
ally higher DOX concentrations of about twice as much in
the liver and three times as much in the spleen were found
for the RBC-DOX group compared to the free DOX group.
The lungs also had a significantly larger concentration of
DOX for the RBC-DOX group. The concentration of large lipo-
somes (5 10mm) in the lungs has been observed previ-
ously, and it is attributed to the effect of bloodborne
macrophages, which tend to engulf the liposomes and then
migrate to the alveoli where they become resident alveolar
macrophages (Poste et al., 1982).
The myelosuppression results also present interesting
findings. For relative white cell in general and lymphocytes,
neutrophils, and eosinophils, the cell count was higher for
the RBC-DOX group than the DOX group, but still lower than
the control group. This suggests that a certain degree of
myelosuppression is still present with the usage of RBC-DOX,
however, not as significant as that present under free DOX.
Interestingly, the monocyte cell count for the RBC-DOX
group is higher than that of both the DOX and control
groups. This serves as evidence of a functioning immune sys-
tem, suggesting that the RBC-DOX induced myelosuppres-
sion is not enough to suppress the immune response. On
the other hand, this is also evidence in favor of an immune
foreign body response to the RBC-DOX. Liposomes have
been shown to cause an immune response when used as
drug delivery alternatives (La-Beck & Gabizon, 2017).
Specifically, pegylated doxorubicin-loaded liposomes can
lead to blood complement immune response activation
upon first exposure, leading to hypersensitivity (Chanan-Khan
et al., 2003). These types of liposomal induced immune
responses were one of the motivations to use RBCs as a
drug carrier alternative. However, RBCs themselves are intri-
cately related to the action of immune system, specifically
monocytes (de Back et al., 2014). The mononuclear phago-
cyte system (MPS), is comprised of monocytes and macro-
phages in the blood, spleen, and liver, which often work
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towards clearing damaged red blood cells (Chanan-Khan
et al., 2003; de Back et al., 2014; La-Beck & Gabizon, 2017). In
this process, cells that are unable to deform through the
endothelial slits of the spleen will then be cleared out by
resident macrophages. Therefore the size, stability, and
mechanical properties of the RBC-DOX liposomes is highly
relevant in order to prevent splenic filtering. The process of
RBC loading with DOX via electroporation is likely to induce
changes in the size, stability, and mechanical properties of
the loaded RBCs. However, our previous studies with RBCs
loaded with different agents via electroporation did not
detect any significant loss in hemoglobin or increased RBC
sequestration after large volume exchange transfusion rela-
tive to the low dose/volume of RBC-DOX used in this study
(Cabrales et al., 2008; Villela et al., 2009). Previous studies
have also reported the changes in cell volume, rheology, and
deformability of RBCs loaded with different agents via elec-
troporation. Results indicate that the process of electropor-
ation to load drugs into RBCs does not significantly affect
their mean corpuscular volume, blood viscosity, or change
their deformability (Cabrales et al., 2008; Villela et al., 2009).
Lastly, the in vivo stability of RBC-DOX in the circulation was
confirmed by the pharmacokinetics of RBC-DOX obtained in
this study, where RBC-DOX presented a half-life of over 3 h,
suggesting that RBCs loaded with DOX via electroporation
can circulate for long periods of time without being trapped
in the spleen and liver. The RBC-DOX’s half-life as well as the
evidence from previous studies showing that minimal
changes in the loaded RBCs’ structural properties result from
the electroporation process, suggest that the accumulation
of DOX in the spleen of RBC-DOX treated animals might be
a result of a change in deformability towards the end of the
RBC-DOX vesicle lifecycle. As the DOX is released from the
RBC vesicle, the corpuscular volume and stiffness might
change leading to eventual filtering by the spleen. Even
small changes in deformability or changes in RBC surface can
be detected by the splenic endothelial slits. This can lead to
an upregulation in the number of splenic macrophages as a
response to an increased number of cells being filtered out
in the spleen. The loading process might have also caused
the loss of some important surface markers in the RBCs. The
absence of some of these markers such as CD47 might trig-
ger a phagocytic response against the RBC which now will
be treated as a foreign body, effectively causing an increase
in circulating monocytes in order to elicit the response
(Oldenborg et al., 2000; de Back et al., 2014).
The systemic hemodynamics and cardiac function results
are all suggestive of decreased cardiac toxicity when using
RBC-DOX as compared to free DOX. The elevated HR, MAP,
CO, SV, EF, SW, and contractility (Figures 4,5) of the RBC-DOX
group, as compared to the DOX group, serve as direct evi-
dence of a more stable cardiovascular performance.
The increased systemic vascular resistance of the free DOX
group is suggestive of the presence of vasoconstriction. This
vasoconstriction can be traced back to the effects of endo-
thelin-1, which has been previously shown to increase in
doxorubicin-treated mice (Bien et al., 2007). Increases in
endothelin-1 are also associated with increases in the
calcium load of cardiomyocytes, eventually leading to apop-
tosis and subsequent cardiac dysfunction (Mitry & Edwards,
2016). Based on this hypothesis, the decreased SVR of the
RBC-DOX group might be indicative of a decreased upregula-
tion of endothelin-1, and therefore, decreased cardiac dam-
age associated with it. Furthermore, endothelin-1 is also
associated with increased myocardial stiffness, which is in
itself directly related to the cardiac dysfunction. This effect
can be observed in the increased LVDP, which is significantly
more elevated in the DOX group, than in the RBC-DOX
group. According to Laplace’s law, elevated pressure sug-
gests elevated wall tension, and elevated wall tension in dia-
stole is often due to increased stiffness. This is further
evidence in favor of decreased cardiac toxicity when using
RBC-DOX as compared to free DOX. As a potential explan-
ation of why RBC-DOX leads to improved cardiac function
relative to free DOX one can look at the biodistribution of
DOX in the heart (Figure 2(C)). For the RBC-DOX group, the
DOX concentration in the heart was almost half of the con-
centration found in the heart for the free DOX group. The
constraining of DOX inside the RBC makes it harder for it to
reach the cardiac tissue when flowing in the highly dynamic
ventricular and aortic flow profiles, as the DOX would not
only have to diffuse from the circulation into the tissue, but
also through the RBC membrane. Furthermore, the likely
alterations in RBC membrane stiffness for RBC-DOX are likely
to decrease the ability for these modified cells to reach the
coronary circulation from the aortic arch, since the behavior
in turbulent flow, for these modified cells, will be different
than the behavior of regular cells. Further studies in this area
are required for a comprehensive understanding of what is
the mechanism for decreased cardiac toxicity.
In most cases, cancer chemotherapy is limited by the low
therapeutic index of the anticancer drugs due to serious tox-
icity to normal tissues. Indeed, the therapy-limiting toxicity
of DOX is cardiomyopathy, which may lead to congestive
heart failure and death (Swain et al., 2003). The goal of load-
ing RBCs with DOX was to improve the biodistribution char-
acteristics and changes the toxicologic properties of DOX.
These studies demonstrated that the accumulation of DOX
from RBC DOX in the skin and heart were significantly lower
than that of free DOX. Tissue levels of DOX were reduced by
RBC-DOX delivery, the decreased concentration of DOX at
these sites is likely to result in a reduced risk of the develop-
ment of side effects. Indeed, the biochemical and hemato-
logical analyses demonstrated that the improved therapeutic
efficacy of RBC-DOX was obtained without an increase in
toxicity to the heart or to the bone marrow. As for the indi-
cators of myelosuppression, the higher level of total white
cell numbers, lymphocytes, and monocytes in the RBC-DOX
group indicated that RBC-DOX decreased the toxicity of mye-
losuppression of the encapsulated drug. The increased accu-
mulation of DOX from RBC-DOX in the liver, spleen, and lung
compared to the free DOX may be related to preferential
accumulation of DOX-loaded RBCs in organs of the reticulo-
endothelial system.
Limitations of this study include the need for a more
comprehensive understanding of what is happening in the
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vascular region near the tumor, as this might elucidate the
mechanism through which RBC-DOX achieves increased anti-
tumorigenic effects. Current studies by our group are
focused on using fluorescently labeled DOX, and RBC-DOX
for visualization in window chamber model implanted
tumors. This will allow to understand the diffusive behavior
of DOX and RBC-DOX as well as verify observation made in
this initial study. Future studies should also focus on deter-
mining the changes in the RBC membrane stiffness induced
by the loading procedure specifically for DOX. This will allow
to determine whether changes in RBC membrane stiffness
might be responsible for the observed biodistribution of the
RBC-DOX. Although, no obvious alteration in spleen function
was observed in the animals treated with RBC-DOX, the
acute and long-term effects of the high DOX accumulation
in the spleen should be explored in future studies. The most
sensitive animal models for each study were used, as it is
impossible to perform all the studies in the same set of ani-
mals. Tumorless mice (C57BL) were used for short term
pharmacokinetics studies, as they are the most frequently
used mice strain for pharmacology. Immunodeficient nude
mice were used for anti-tumor evaluation, because they
allow for the evaluation of xenograft tumors, although they
were not used for pharmacokinetics and cardiotoxicity stud-
ies because they do not represent normal human physiology
due to their inhibited immune system. BALB/C were used for
cardiotoxicity studies as they can tolerate higher cumulative
doses of DOX with a well-defined phenotype of DOX-
induced cardiotoxicity, including decreased cardiac systolic
function, ventricular enlargement, and other similar histo-
logical alterations to those occurring in humans exposed to
DOX. Future studies with RBC-DOX should include a side-by-
side comparison to clinically relevant current ways to admin-
ister DOX, in the form of pegylated liposomal doxorubicin,
DoxilVR , including the aspects measured in the current study
and evaluation of their removal pathways. Clinical results
indicate that DoxilVR is cardiotoxic with increasing cumulative
dose, and liposomes like DoxilVR and other particulate deliv-
ery systems, depend on the reticuloendothelial system for
removal. DoxilVR clearance is mediated by the fixed macro-
phages of the liver, spleen, and lungs that constitute the
reticuloendothelial system and is assisted by opsonins that
facilitate macrophage uptake of foreign particulates, whereas
RBC are removed by liver macrophages (Kupffer cells) or cap-
tured and metabolized in the spleen and spleen. Therefore,
comparison on the implication of their removal process
should be studied carefully in the future.
Conclusion
This study successfully demonstrated a simple procedure for
loading DOX into RBCs. It also demonstrated that RBC-DOX
has increased antitumorigenic effects, and decreased myelo-
suppression and cardiac toxicity when compared to equiva-
lent administrations of free DOX. These results should
encourage the further development of studies to better
understand the potential long-term effects of this line of
treatment, as well as ways to efficiently translate this meth-
odology into a clinically relevant setting.
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